2,2'-Dinitrobiphenyl

Product information

2,2'-Dinitrobiphenyl

CAS No.
2436-96-6
Formula
C₁₂H₈N₂O₄
Molecular weight
244.20 g/mol

Backed by process development and scale-up capabilities, Capot can provide stable kilogram-to-commercial-scale supply of 2,2'-Dinitrobiphenyl and support custom specifications.

2,2'-Dinitrobiphenyl

Product overview

2,2'-Dinitrobiphenyl is an aromatic nitro compound, with a nitro group that changes the ring’s electron distribution and can be transformed into an amino group.

Application areas

Depending on the synthesis route and project requirements, this product may also be suitable for other related organic synthesis applications.

Potential uses

  • It may provide access to the corresponding substituted aniline through controlled nitro reduction, subject to tolerance of the other substituents.

Production & quality support

Quality support

  • Process development, optimization and scale-up
  • Analytical testing and quality control
  • Batch documentation and technical information support

Scale & supply

  • Commercial manufacturing and supply capabilities from kilogram to ton scale
  • Assessment of customer specifications and quality requirements
  • Long-term reliable supply support

Supply scale:Kilogram scale

Available documents

  • Product specification (SPEC)
  • Safety data sheet (SDS)
  • Certificate of analysis (COA)
  • Route of synthesis (ROS)
  • Method of analysis (MOA)
  • Analytical data
  • Regulatory and quality declarations

Related documents may be evaluated and provided based on the product, project stage, progress of cooperation, and confidentiality requirements.

Website information is for reference only. For product specifications and related materials, please refer to the final official documents confirmed by our company.

Custom requirements

Describe any specific specification, packaging or technical support requirements in your inquiry.
Discuss custom synthesis →

Start a conversation

Request a quote

Tell us the quantity and technical requirements. We will follow up shortly.